Jill Pulley has focused her career on providing disease-neutral, large-scale infrastructure so that researchers can initiate and conduct high quality translational science in a compliant, efficient, and cost effective manner. She is Executive Director of the Vanderbilt Institute for Clinical and Translational Research (VICTR, Vanderbilt’s CTSA) and the director of a new Drug Repurposing program. The program leverages BioVU, Vanderbilt’s DNA biorepository linked to longitudinal clinical data.